Digital health funding increases in 2025, spurred by AI: report

Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total funding, according to Rock Health.

By Emily Olsen • Jan. 13, 2026

JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors. 

By BioPharma Dive staff • Jan. 12, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.

By BioPharma Dive staff • Jan. 12, 2026

5 questions facing biopharma in 2026

The biopharmaceutical sector finally regained its footing in 2025. Here are five issues that could determine whether the renewed optimism will carry over into the new year.

By BioPharma Dive staff • Jan. 12, 2026

Eikon, a high-profile startup led by Merck vets, seeks an IPO

Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a group of experimental cancer drugs. 

By Ben Fidler • Jan. 11, 2026

Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

By BioPharma Dive staff • Jan. 9, 2026

Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments for rare conditions by using the agency’s “plausible mechanism” pathway.

By Ben Fidler • Jan. 9, 2026

Aktis raises $318M in 2026’s first biotech IPO

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.

By Gwendolyn Wu • Jan. 8, 2026

Alveus launches with $160M to advance MariTide-like obesity drug

The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as well as an amylin-targeting weight loss medicine.

By Jonathan Gardner • Jan. 8, 2026

Parabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz

The financing, which will back a novel type of cancer drug, is the largest of a series of startup fundings announced at the top of 2026.

By Kristin Jensen • Jan. 8, 2026

Diagonal banks another $125M for ‘clustering’ antibody drugs

Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of treating two disparate conditions, one of which is the target of Merck’s fast-selling Winrevair. 

By Gwendolyn Wu • Jan. 8, 2026

EpiBiologics raises $107M for its protein-degrading cancer drug

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of several marketed therapies.

By Gwendolyn Wu • Jan. 8, 2026

Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got less crowded and Amgen and Lilly struck startup deals.

By BioPharma Dive staff • Jan. 7, 2026

Alumis soars as TYK2 drug hits mark in psoriasis trials

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.

By Jonathan Gardner • Jan. 6, 2026

Amgen buys protein-degrading startup Dark Blue for up to $840M

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that could set it apart from current medications. 

By Gwendolyn Wu • Jan. 6, 2026

Moderna, searching for a rebound, to seek approval of mRNA flu shot

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead. 

By Delilah Alvarado • Jan. 5, 2026

Zenas shares crash after top drug misses expectations in immune disease study

While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.

By Jonathan Gardner • Jan. 5, 2026

Novo launches Wegovy pill; Argenx to swap CEOs

Novo Nordisk officially began marketing the pill version of its popular weight loss drug. Elsewhere, Sanofi bought a vaccine maker and an eczema therapy J&J acquired in a billion-dollar deal failed a key test. 

By Ben Fidler • Jan. 5, 2026

10 clinical trials to watch in the first half of 2026

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and many rare conditions could help it continue.

By BioPharma Dive staff • Jan. 5, 2026

Biopharma CEO optimism is wavering in the US

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

By Kelly Bilodeau • Dec. 23, 2025

Trump to test ‘most favored nation’ pricing for Medicare; Shionogi pays $2.5B for ALS drug

Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise.

By BioPharma Dive staff • Dec. 22, 2025

Radiopharmaceutical specialist Aktis seeks an IPO

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.

By Ben Fidler • Dec. 22, 2025

Cytokinetics set to battle Bristol Myers as FDA approves heart drug

The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which is on its way to topping $1 billion in sales this year.

By Ben Fidler • Dec. 21, 2025

BioMarin to buy rare disease drugmaker Amicus for $4.8B

Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies that generated nearly $450 million over the first nine months of this year.

By Jacob Bell • Dec. 19, 2025

Novo files for CagriSema approval; Merck and Pfizer’s trial win

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

By BioPharma Dive staff • Dec. 19, 2025